Clofazimine

證據等級: L5

預測適應症: 3 個

Clofazimine: From Leprosy to Pneumocystosis

One-Sentence Summary

Clofazimine is a riminophenazine antimycobacterial agent internationally established as a core component of multidrug therapy (MDT) for leprosy (Hansen’s disease); this specific therapeutic use is not captured in the current evidence pack. The TxGNN model predicts it may be relevant to Pneumocystosis management in immunocompromised patients, with 1 completed clinical trial and 4 supporting publications currently available — though the trial and most literature concern prophylaxis of a co-occurring opportunistic infection (Mycobacterium avium complex, MAC) in patients with a history of pneumocystosis, rather than direct anti-Pneumocystis activity.

Quick Overview

Item	Content
Original Indication	Leprosy (multibacillary), as part of multidrug therapy — based on established international use; not recorded in this evidence pack
Predicted New Indication	Pneumocystosis
TxGNN Prediction Score	99.90%
Evidence Level	L3
UK Market Status	Not marketed (no MHRA authorisation currently on file)
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data for clofazimine is not available in this evidence pack. Based on known information, clofazimine is a riminophenazine antimycobacterial agent used in combination therapy for leprosy, with recognised anti-inflammatory and immunomodulatory activity in addition to its antimycobacterial effect. This broader immunomodulatory profile is a plausible mechanistic link to management of opportunistic infections in immunocompromised hosts, which is the context in which the supporting evidence arises.

Importantly, the available clinical trial and most of the literature relate to clofazimine’s use as prophylaxis against Mycobacterium avium complex (MAC) infection in HIV-positive patients who had already experienced an episode of Pneumocystis carinii (now jirovecii) pneumonia, or who had low CD4 counts — not to direct treatment of pneumocystosis itself. The overlap arises because both conditions occur in the same severely immunocompromised (advanced HIV/AIDS) patient population, rather than through a demonstrated direct antiparasitic/antifungal effect of clofazimine against Pneumocystis.

This distinction matters clinically: the current evidence supports a rationale for further investigation of clofazimine’s role in the broader management of opportunistic infection risk in immunocompromised patients, but does not itself demonstrate efficacy against pneumocystosis as a standalone indication.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT00002058	Not specified (NA)	Completed	N/A	Randomised controlled study evaluating clofazimine prophylaxis against Mycobacterium avium complex (MAC) infection in HIV-infected individuals at risk of this opportunistic disease; conducted in the pre-effective-antiretroviral-therapy era.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
8501340	1993	RCT	The Journal of Infectious Diseases	Randomised, prospective, open-label, treatment-vs-no-treatment trial (n=110) of clofazimine 50mg/day as prophylaxis against disseminated MAC infection in HIV patients with a prior episode of Pneumocystis carinii pneumonia or CD4 ≤100/mm³.
11363899	1996	Review	PI Perspective	Update summarising management approaches to opportunistic infections, including clofazimine, in HIV/AIDS.
6299154	1983	Case report	Annals of Internal Medicine	Case of a 27-year-old man with haemophilia presenting with Pneumocystis carinii pneumonia followed by disseminated Mycobacterium avium-intracellulare, an early AIDS-defining case series.
2714863	1989	Case report	Infection	AIDS patient with Mycobacterium kansasii lung disease complicated by Pneumocystis carinii pneumonia; combination therapy including clofazimine led to sustained clinical recovery.

Safety Considerations

A Blocking data gap has been identified: TFDA/SmPC-equivalent warnings and contraindications for clofazimine are not currently available in this evidence pack, which prevents completion of even an initial (S1) safety screening. No drug–drug interaction data were retrieved.

Please refer to the SmPC and BNF for safety information once available. Report suspected adverse reactions via the Yellow Card Scheme.

Conclusion and Next Steps

Decision: Hold

Rationale: The drug currently has no UK marketing authorisation and a Blocking data gap exists for core safety information (warnings/contraindications), preventing an initial safety assessment. In addition, the supporting evidence primarily demonstrates clofazimine’s role in preventing a concurrent opportunistic infection (MAC) in patients who have already had pneumocystosis, rather than direct efficacy against pneumocystosis itself, so the mechanistic rationale for this specific indication remains unconfirmed.

To proceed, the following is needed:

TFDA/MHRA SmPC data (warnings, contraindications) to complete initial safety screening (resolves DG001)
Confirmed mechanism of action data (resolves DG002)
Studies evaluating direct anti-Pneumocystis jirovecii activity, as distinct from MAC co-prophylaxis
Clarification of UK regulatory/market pathway, given the drug is not currently marketed in the UK
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.